This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, Nh Theraguix, The Brigham and Women's Hospital, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2026
Title: Olivier Tillement: Innovator in Nanoparticle Technology
Introduction
Olivier Tillement is a notable inventor based in Fontaines Saint Martin, France. He has made significant contributions to the field of nanoparticle technology, particularly in the area of medical imaging and cancer treatment. His innovative work has led to the development of a unique patent that showcases his expertise and dedication to advancing healthcare solutions.
Latest Patents
Olivier Tillement holds a patent for "Bismuth-gadolinium nanoparticles." This patent describes nanoparticle compositions that include high atomic number ions, which are useful for imaging diseases and radiosensitizing conditions such as cancer in subjects. The patent also outlines methods for imaging, treating cancer, and processes for preparing these nanoparticle compositions. This invention represents a significant advancement in the field of medical technology.
Career Highlights
Throughout his career, Olivier Tillement has worked with prestigious institutions, including The Brigham and Women's Hospital, Inc. and Université Claude Bernard Lyon 1. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Olivier has collaborated with notable colleagues such as Ross Berbeco and Eloise Thomas. These partnerships have further enriched his research and development efforts, leading to innovative solutions in nanoparticle technology.
Conclusion
Olivier Tillement's work in nanoparticle technology exemplifies the impact of innovation in medical science. His patent for bismuth-gadolinium nanoparticles highlights his commitment to improving disease imaging and treatment methods. Through his career and collaborations, he continues to contribute to advancements that can benefit healthcare significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile